细胞外囊泡作为新一代药物药代动力学和药效学调节剂及其作为辅助疗法的潜力

IF 7.9 1区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL
Jiaqi Liu, Joel Z. Nordin, Andrew J. McLachlan, Wojciech Chrzanowski
{"title":"细胞外囊泡作为新一代药物药代动力学和药效学调节剂及其作为辅助疗法的潜力","authors":"Jiaqi Liu,&nbsp;Joel Z. Nordin,&nbsp;Andrew J. McLachlan,&nbsp;Wojciech Chrzanowski","doi":"10.1002/ctm2.70002","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background and main body</h3>\n \n <p>Pharmacokinetics (PK) and pharmacodynamics (PD) are central concepts to guide the dosage and administration of drug therapies and are essential to consider for both healthcare professionals and researchers in therapeutic planning and drug discovery. PK/PD properties of a drug significantly influence variability in response to treatment, including therapeutic failure or excessive medication-related harm. Furthermore, suboptimal PK properties constitute a significant barrier to further development for some candidate treatments in drug discovery. This article describes how extracellular vesicles (EVs) affect different aspects of PK and PD of medications and their potential to modulate PK and PD properties to address problematic PK/PD profiles of drugs. We reviewed EVs' intrinsic effects on cell behaviours and medication responses. We also described how surface and cargo modifications can enhance EV functionalities and enable them as adjuvants to optimise the PK/PD profile of conventional medications. Furthermore, we demonstrated that various bioengineering strategies can be used to modify the properties of EVs, hence enhancing their potential to modulate PK and PD profile of medications.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>This review uncovers the critical role of EVs in PK and PD modulation and motivates further research and the development of assays to unfold EVs’ full potential in solving PK and PD-related problems. However, while we have shown that EVs play a vital role in modulating PK and PD properties of medications, we postulated that it is essential to define the context of use when designing and utilising EVs in pharmaceutical and medical applications.</p>\n </section>\n \n <section>\n \n <h3> Highlights</h3>\n \n <div>\n <ul>\n \n <li>Existing solutions for pharmacokinetics and pharmacodynamics modulation are limited.</li>\n \n <li>Extracellular vesicles can optimise pharmacokinetics as a drug delivery vehicle.</li>\n \n <li>Biogenesis and administration of extracellular vesicles can signal cell response.</li>\n \n <li>The pharmaceutical potential of extracellular vesicles can be enhanced by surface and cargo bioengineering.</li>\n \n <li>When using extracellular vesicles as modulators of pharmacokinetics and pharmacodynamics, the ‘context of use’ must be considered.</li>\n </ul>\n </div>\n </section>\n </div>","PeriodicalId":10189,"journal":{"name":"Clinical and Translational Medicine","volume":"14 8","pages":""},"PeriodicalIF":7.9000,"publicationDate":"2024-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ctm2.70002","citationCount":"0","resultStr":"{\"title\":\"Extracellular vesicles as the next-generation modulators of pharmacokinetics and pharmacodynamics of medications and their potential as adjuvant therapeutics\",\"authors\":\"Jiaqi Liu,&nbsp;Joel Z. Nordin,&nbsp;Andrew J. McLachlan,&nbsp;Wojciech Chrzanowski\",\"doi\":\"10.1002/ctm2.70002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background and main body</h3>\\n \\n <p>Pharmacokinetics (PK) and pharmacodynamics (PD) are central concepts to guide the dosage and administration of drug therapies and are essential to consider for both healthcare professionals and researchers in therapeutic planning and drug discovery. PK/PD properties of a drug significantly influence variability in response to treatment, including therapeutic failure or excessive medication-related harm. Furthermore, suboptimal PK properties constitute a significant barrier to further development for some candidate treatments in drug discovery. This article describes how extracellular vesicles (EVs) affect different aspects of PK and PD of medications and their potential to modulate PK and PD properties to address problematic PK/PD profiles of drugs. We reviewed EVs' intrinsic effects on cell behaviours and medication responses. We also described how surface and cargo modifications can enhance EV functionalities and enable them as adjuvants to optimise the PK/PD profile of conventional medications. Furthermore, we demonstrated that various bioengineering strategies can be used to modify the properties of EVs, hence enhancing their potential to modulate PK and PD profile of medications.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>This review uncovers the critical role of EVs in PK and PD modulation and motivates further research and the development of assays to unfold EVs’ full potential in solving PK and PD-related problems. However, while we have shown that EVs play a vital role in modulating PK and PD properties of medications, we postulated that it is essential to define the context of use when designing and utilising EVs in pharmaceutical and medical applications.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Highlights</h3>\\n \\n <div>\\n <ul>\\n \\n <li>Existing solutions for pharmacokinetics and pharmacodynamics modulation are limited.</li>\\n \\n <li>Extracellular vesicles can optimise pharmacokinetics as a drug delivery vehicle.</li>\\n \\n <li>Biogenesis and administration of extracellular vesicles can signal cell response.</li>\\n \\n <li>The pharmaceutical potential of extracellular vesicles can be enhanced by surface and cargo bioengineering.</li>\\n \\n <li>When using extracellular vesicles as modulators of pharmacokinetics and pharmacodynamics, the ‘context of use’ must be considered.</li>\\n </ul>\\n </div>\\n </section>\\n </div>\",\"PeriodicalId\":10189,\"journal\":{\"name\":\"Clinical and Translational Medicine\",\"volume\":\"14 8\",\"pages\":\"\"},\"PeriodicalIF\":7.9000,\"publicationDate\":\"2024-08-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ctm2.70002\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical and Translational Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/ctm2.70002\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Translational Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/ctm2.70002","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

摘要

背景和正文 药代动力学(PK)和药效学(PD)是指导药物治疗剂量和给药的核心概念,也是医护人员和研究人员在制定治疗计划和进行药物研发时必须考虑的因素。药物的 PK/PD 特性极大地影响着治疗反应的变化,包括治疗失败或与药物相关的过度伤害。此外,在药物发现过程中,不理想的 PK 特性会严重阻碍某些候选疗法的进一步开发。本文介绍了细胞外囊泡(EVs)如何影响药物PK和PD的不同方面,以及它们调节PK和PD特性以解决药物PK/PD谱问题的潜力。我们回顾了EVs对细胞行为和药物反应的内在影响。我们还介绍了表面和货物修饰如何增强 EV 的功能,并使其成为优化传统药物 PK/PD 特征的佐剂。此外,我们还展示了各种生物工程策略可用于改变 EVs 的特性,从而增强其调节药物 PK 和 PD 谱的潜力。 结论 本综述揭示了 EVs 在 PK 和 PD 调节中的关键作用,并激励人们进一步研究和开发检测方法,以充分发挥 EVs 在解决 PK 和 PD 相关问题方面的潜力。不过,虽然我们已经证明了 EVs 在调节药物 PK 和 PD 特性方面发挥着重要作用,但我们认为,在设计和利用 EVs 进行制药和医疗应用时,必须明确使用环境。 亮点 用于药代动力学和药效学调节的现有解决方案非常有限。 细胞外囊泡作为一种给药载体可以优化药代动力学。 细胞外囊泡的生物生成和给药可发出细胞反应信号。 细胞外囊泡的制药潜力可通过表面和货物生物工程得到增强。 将细胞外囊泡用作药代动力学和药效学调节剂时,必须考虑 "使用环境"。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Extracellular vesicles as the next-generation modulators of pharmacokinetics and pharmacodynamics of medications and their potential as adjuvant therapeutics

Extracellular vesicles as the next-generation modulators of pharmacokinetics and pharmacodynamics of medications and their potential as adjuvant therapeutics

Background and main body

Pharmacokinetics (PK) and pharmacodynamics (PD) are central concepts to guide the dosage and administration of drug therapies and are essential to consider for both healthcare professionals and researchers in therapeutic planning and drug discovery. PK/PD properties of a drug significantly influence variability in response to treatment, including therapeutic failure or excessive medication-related harm. Furthermore, suboptimal PK properties constitute a significant barrier to further development for some candidate treatments in drug discovery. This article describes how extracellular vesicles (EVs) affect different aspects of PK and PD of medications and their potential to modulate PK and PD properties to address problematic PK/PD profiles of drugs. We reviewed EVs' intrinsic effects on cell behaviours and medication responses. We also described how surface and cargo modifications can enhance EV functionalities and enable them as adjuvants to optimise the PK/PD profile of conventional medications. Furthermore, we demonstrated that various bioengineering strategies can be used to modify the properties of EVs, hence enhancing their potential to modulate PK and PD profile of medications.

Conclusion

This review uncovers the critical role of EVs in PK and PD modulation and motivates further research and the development of assays to unfold EVs’ full potential in solving PK and PD-related problems. However, while we have shown that EVs play a vital role in modulating PK and PD properties of medications, we postulated that it is essential to define the context of use when designing and utilising EVs in pharmaceutical and medical applications.

Highlights

  • Existing solutions for pharmacokinetics and pharmacodynamics modulation are limited.
  • Extracellular vesicles can optimise pharmacokinetics as a drug delivery vehicle.
  • Biogenesis and administration of extracellular vesicles can signal cell response.
  • The pharmaceutical potential of extracellular vesicles can be enhanced by surface and cargo bioengineering.
  • When using extracellular vesicles as modulators of pharmacokinetics and pharmacodynamics, the ‘context of use’ must be considered.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
15.90
自引率
1.90%
发文量
450
审稿时长
4 weeks
期刊介绍: Clinical and Translational Medicine (CTM) is an international, peer-reviewed, open-access journal dedicated to accelerating the translation of preclinical research into clinical applications and fostering communication between basic and clinical scientists. It highlights the clinical potential and application of various fields including biotechnologies, biomaterials, bioengineering, biomarkers, molecular medicine, omics science, bioinformatics, immunology, molecular imaging, drug discovery, regulation, and health policy. With a focus on the bench-to-bedside approach, CTM prioritizes studies and clinical observations that generate hypotheses relevant to patients and diseases, guiding investigations in cellular and molecular medicine. The journal encourages submissions from clinicians, researchers, policymakers, and industry professionals.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信